GLP-1 receptor agonists should be discontinued before attempting pregnancy. The exact washout period varies by medication: semaglutide products require at least two months, while tirzepatide products need at least one month. Despite this restriction, the weight loss these medications enable can significantly improve fertility for patients struggling with obesity-related reproductive problems.

The GLP-1 medication class includes semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda, Victoza), and several others. All of them carry pregnancy-related precautions, and all of them can produce metabolic changes that benefit reproductive health indirectly. Understanding the class-wide picture helps you make informed decisions regardless of which specific GLP-1 you are taking.

Why GLP-1 Medications Are Stopped Before Pregnancy

None of the currently available GLP-1 receptor agonists are approved for use during pregnancy. Animal reproductive studies across the class have shown adverse developmental effects at doses above human therapeutic ranges, including embryonic loss, reduced fetal growth, and skeletal abnormalities.

Human pregnancy data is limited for all GLP-1 medications because pregnant women are excluded from clinical trials. The washout recommendations are precautionary, designed to ensure the drug is cleared before conception occurs. Different half-lives across the class dictate different washout timelines:

• Semaglutide (Ozempic, Wegovy, compounded): approximately 7-day half-life, 2-month washout
• Tirzepatide (Mounjaro, Zepbound): approximately 5-day half-life, 1-month washout
• Liraglutide (Saxenda, Victoza): approximately 13-hour half-life, shorter washout (consult provider)

The Fertility Paradox: GLP-1 Weight Loss as a Fertility Treatment

While GLP-1 medications must be stopped before pregnancy, the weight loss they produce can be one of the most effective pre-conception interventions available. Obesity affects fertility through several interconnected mechanisms:

• Excess fat tissue produces estrogen, disrupting the hormonal signals that trigger ovulation
• Insulin resistance, common in obesity, impairs follicular development and egg maturation
• Chronic inflammation associated with excess weight reduces egg and sperm quality
• Higher BMI is linked to lower IVF success rates and higher miscarriage rates

By addressing these factors through meaningful weight loss, GLP-1 medications can create a more fertile foundation even though the drugs themselves cannot be taken during pregnancy. Some reproductive endocrinologists have begun incorporating GLP-1 therapy into pre-conception planning for obese patients.

GLP-1 Medications and PCOS

PCOS is one of the most common causes of female infertility, affecting 8% to 13% of reproductive-age women globally. The condition is closely tied to insulin resistance and weight gain, making GLP-1 medications a particularly relevant treatment option.

Weight loss and improved insulin sensitivity from GLP-1 therapy can restore regular ovulation in many PCOS patients. This restoration can happen unexpectedly, leading to unplanned pregnancies in women who thought they could not conceive. If you have PCOS and are taking a GLP-1 medication without intending to become pregnant, use reliable contraception consistently.

Contraception Across the GLP-1 Class

All GLP-1 receptor agonists slow gastric emptying to varying degrees. This raises theoretical concerns about oral contraceptive pill absorption. Tirzepatide's prescribing information is the most explicit, recommending backup contraception for four weeks after initiation and dose changes. Semaglutide's label is less specific but acknowledges the possibility. Non-oral methods (IUDs, implants, injections, patches) bypass this concern entirely.

Frequently Asked Questions